Phase 4
N=90
Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department
Pain
Bottom Line
View on ClinicalTrials.gov: NCT01835262 ↗Enrolled (actual)
90
Serious AEs
0.0%
Results posted
Aug 2015
Primary outcome: Primary: Numeric Rating Scale of Pain — 3.93; 4.07 Units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Morphine (Drug); Ketamine (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Antonios Likourezos
- Primary completion
- May 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Numeric Rating Scale of Pain |
3.93; 4.07 | — |
Summary
The primary objectives of the study are to evaluate the efficacy of subdissociative dose intravenous ketamine compared with intravenous morphine in relieving acute pain in the ED. Secondary objectives will include the rate of adverse effects and need for rescue analgesia. The hypothesis is that intravenous administration of subdissociative dose ketamine at 0.3 mg/kg is superior to intravenous morphine at 0.1mg/kg in treating moderate and severe acute pain in patients presenting to the ED.
Eligibility Criteria
Inclusion Criteria
- ED patients18-55 years old presenting with moderate to severe (Numeric Pain Rating Score >5) acute (less than 7 days)
- abdominal, flank, back or musculoskeletal pain warranting (in the treating physician's judgment) administration of intravenous opioid pain medication.
- Patients must be awake, alert and oriented to time, place and person,
- patient must be able to demonstrate understanding of the informed consent.
- Patient must be able to verbalize how much pain they are having on the 10 point Numeric Rating Pain Scale,
- Patient mus be able to verbalize the nature of the side effects he may be experiencing from the intravenous analgesia.
Exclusion Criteria
- Pregnancy or breast feeding
- SBP 180
- HR 150
- RR 30
- administration of opiate pain medication in the past 4 hours prior to assessment (i.e. home, EMS, triage, office, etc.)
- presence of renal or hepatic insufficiency (as assessed by electronic chart review),
Data sourced from ClinicalTrials.gov (NCT01835262). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.